{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.8","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"CRR was defined as the percentage of participants who achieved minor response (MR) or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. MR: \\>=25% but less than (\\<) 50% reduction of serum IgM from baseline.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From start of the treatment (Day 1) up to 49.3 months","title":"Clinical Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}